Phase I Study Combining Elotuzumab with Autologous Stem Cell Transplant and Lenalidomide for Multiple Myeloma

The authors conducted a Phase I clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma previously treated with induction therapy.
[Journal For Immunotherapy Of Cancer]